Management of metastatic renal cell carcinoma – mini review

Main Article Content

Anubha Bharthuar
Himanshu Pandey
Swapan Sood

Keywords

Metastatic renal cell carcinoma, Prognostic models, Targeted therapy

Abstract

The management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the last decade. A number of different systemic molecular targeted agents that have been recently approved have improved the survival of patients with mRCC. This mini-review focuses on the implementation of multi-modality therapy in the management of mRCC and the approved indications of the various available novel agents. These novel agents have expanded our armamentarium and improved clinical outcomes of this challenging disease that has considerable biological heterogeneity and clinical variability.

Abstract 2212 | PDF Downloads 1087 HTML Downloads 1824

References

1.http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/kidney-cancer-statistics.

2. Gupta K1, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193-205. Doi: http://dx.doi.org/10.1016/j.ctrv.2007.12.001

3. Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008;15(2):3954-66.

4. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-40.

5. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-96. Doi: http://dx.doi.org/10.1200/JCO.20.1.289

6. Mekhail TM1, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832-41. Doi: http://dx.doi.org/10.1200/JCO.2005.05.179

7. Heng DY et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-9. Doi: http://dx.doi.org/10.1200/JCO.2008.21.4809

8. Heng DY et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141-8. Doi: http://dx.doi.org/10.1016/S1470-2045(12)70559-4

9. Flanigan RC1, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071-6. Doi: http://dx.doi.org/10.1097/01.ju.0000110610.61545.ae

10. https://clinicaltrials.gov/ct2/show/NCT00930033

11. https://clinicaltrials.gov/ct2/show/NCT01099423

12. Heng DY et al. Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Genitourinary Cancers Symposium. J Clin Oncol 32, 2014 (suppl 4; abstr 396).

13. Kim DY, Karam JA, Wood CG. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol. 2014;32(3):631-42.
Doi: http://dx.doi.org/10.1007/s00345-014-1293-6

14. Ljungberg B. The role of metastasectomy in renal cell carcinoma in the era of targeted therapy. Curr Urol Rep. 2013;14(1):19-25. Doi: http://dx.doi.org/10.1007/s11934-012-0293-6

15. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271(12):907-13. Doi: http://dx.doi.org/10.1001/jama.1994.03510360033032

16. Yang JC et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127-32.
Doi: http://dx.doi.org/10.1200/JCO.2003.02.122

17. McDermott DF et al. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(3):561-8. Doi: http://dx.doi.org/10.1158/1078-0432.CCR-14-1520

18. Coppin C1, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425.

19. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist. 2011;16 Suppl 2:4-13.
Doi: http://dx.doi.org/10.1634/theoncologist.2011-S2-04

20. George DJ, Kaelin WG. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003;349(5):419–21. Doi: http://dx.doi.org/10.1056/NEJMp030061

21. Escudier B et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103–11.
Doi: http://dx.doi.org/10.1016/S0140-6736(07)61904-7

22. Escudier B1, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28(13):2144–50. Doi: http://dx.doi.org/10.1200/JCO.2009.26.7849

23. Rini BI et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. Doi: http://dx.doi.org/10.1200/JCO.2009.26.5561

24. McDermot DF et al. The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC). J Clin Oncol 31, 2013 (suppl 6; abstr 345).

25. Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115–24. Doi: http://dx.doi.org/10.1056/NEJMoa065044

26. Sternberg CN et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8.
Doi: http://dx.doi.org/10.1200/JCO.2009.23.9764

27. Motzer RJ et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-31. Doi: http://dx.doi.org/10.1056/NEJMoa1303989

28. Escudier B et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014;32(14):1412-8. Doi: http://dx.doi.org/10.1200/JCO.2013.50.8267

29. Escudier B et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(8):1280-9.
Doi: http://dx.doi.org/10.1200/JCO.2008.19.3342

30. Escudier B et al. Sorafenib for treatment of renal cell carcinoma:final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312–8. Doi: http://dx.doi.org/10.1200/JCO.2008.19.5511

31. Rini B et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-9.
Doi: http://dx.doi.org/10.1016/S0140-6736(11)61613-9

32. Escudier B et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014;110(12):2821-8.
Doi: http://dx.doi.org/10.1038/bjc.2014.244

33. Hudes G et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81. Doi: http://dx.doi.org/10.1056/NEJMoa066838

34. Motzer RJ et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-65.
Doi: http://dx.doi.org/10.1002/cncr.25219

35. Escudier BJ, Negrier S, Gravis G, Chevreau C, Delva R, Bay J, Geoffrois L, Legouffe E, Blanc E, Ferlay C. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol 28:15s, 2010 (suppl; abstr 4516).\

36. http://clinicaltrials.gov/ct2/show/NCT00631371

37. Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM, Clark BL, Rubin MS, Trent DF, Burris HA 3rd. Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma. J Clin Oncol. 2010;28(13):2131-6. Doi: http://dx.doi.org/10.1200/JCO.2009.26.3152

38. http://clinicaltrials.gov/ct2/show/NCT01198158

39. http://clinicaltrials.gov/ct2/show/NCT00719264

40. http://clinicaltrials.gov/ct2/show/NCT00378703

41. Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28(4):435-41. Doi: http://dx.doi.org/10.1097/00000478-200404000-00002

42. Haas NB1, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012;29(2):761-7. Doi: http://dx.doi.org/10.1007/s12032-011-9829-8

43. Tannir NM1, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008;180(3):867-72; discussion 872. Doi: http://dx.doi.org/10.1016/j.juro.2008.05.017

44. Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ; Cancer and Leukemia Group B. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006;107(6):1273-9. Doi: http://dx.doi.org/10.1002/cncr.22117

45. Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol. 2011;29(8):e203-5. Doi: http://dx.doi.org/10.1200/JCO.2010.31.6091

46. Oudard S et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol. 2007;177(5):1698-702. Doi: http://dx.doi.org/10.1016/j.juro.2007.01.063

47. Maroja Silvino MC1, Venchiarutti Moniz CM, Munhoz Piotto GH, Siqueira S, Galapo Kann A, Dzik C. Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil. Rare Tumors. 2013;5(3):e44. Doi: http://dx.doi.org/10.4081/rt.2013.e44

48. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98(5):962-9. Doi: http://dx.doi.org/10.1002/cncr.11571

49. Broom RJ et al. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial. Clin Genitourin Cancer. 2015;13(1):50-8.
Doi: http://dx.doi.org/10.1016/j.clgc.2014.07.002

50. Henry DH et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-32. Doi: http://dx.doi.org/10.1200/JCO.2010.31.3304